Pasithea Therapeutics KTTA Stock
Pasithea Therapeutics Price Chart
Pasithea Therapeutics KTTA Financial and Trading Overview
| Pasithea Therapeutics stock price | 0.64 USD |
| Previous Close | 0.72 USD |
| Open | 0.7 USD |
| Bid | 0.51 USD x 100 |
| Ask | 0.91 USD x 200 |
| Day's Range | 0.69 - 0.74 USD |
| 52 Week Range | 0.28 - 2.06 USD |
| Volume | 548.7K USD |
| Avg. Volume | 462.15K USD |
| Market Cap | 23.89M USD |
| Beta (5Y Monthly) | 0.224 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3 USD |
KTTA Valuation Measures
| Enterprise Value | -26509046 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7079208 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.32529572 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.538 |
Trading Information
Pasithea Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.224 |
| 52-Week Change | -22.28% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 2.06 USD |
| 52 Week Low | 0.28 USD |
| 50-Day Moving Average | 0.75 USD |
| 200-Day Moving Average | 0.82 USD |
KTTA Share Statistics
| Avg. Volume (3 month) | 462.15K USD |
| Avg. Daily Volume (10-Days) | 485.31K USD |
| Shares Outstanding | 33.41M |
| Float | 18.68M |
| Short Ratio | 0.69 |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 60.04% |
| Shares Short | 297.46K |
| Short % of Float | 0.89% |
| Short % of Shares Outstanding | 0.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.49% |
| Return on Equity (ttm) | -58.22% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -17232384 USD |
| Net Income Avi to Common (ttm) | -19733928 USD |
| Diluted EPS (ttm) | -1.42 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 50.4M USD |
| Total Cash Per Share (mrq) | 1.51 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 35.402 |
| Book Value Per Share (mrq) | 2.198 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16942952 USD |
| Levered Free Cash Flow (ttm) | -11838196 USD |
Profile of Pasithea Therapeutics
| Country | United States |
| State | FL |
| City | Miami Beach |
| Address | 1111 Lincoln Road |
| ZIP | 33139 |
| Phone | 786 977 3380 |
| Website | https://www.pasithea.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Q&A For Pasithea Therapeutics Stock
What is a current KTTA stock price?
Pasithea Therapeutics KTTA stock price today per share is 0.64 USD.
How to purchase Pasithea Therapeutics stock?
You can buy KTTA shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pasithea Therapeutics?
The stock symbol or ticker of Pasithea Therapeutics is KTTA.
Which industry does the Pasithea Therapeutics company belong to?
The Pasithea Therapeutics industry is Biotechnology.
How many shares does Pasithea Therapeutics have in circulation?
The max supply of Pasithea Therapeutics shares is 33.41M.
What is Pasithea Therapeutics Price to Earnings Ratio (PE Ratio)?
Pasithea Therapeutics PE Ratio is now.
What was Pasithea Therapeutics earnings per share over the trailing 12 months (TTM)?
Pasithea Therapeutics EPS is -1.42 USD over the trailing 12 months.
Which sector does the Pasithea Therapeutics company belong to?
The Pasithea Therapeutics sector is Healthcare.
Pasithea Therapeutics KTTA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}